Edvard Wigren

Edvard Wigren

Auto-generated profile, based on publicly available information

Edvard Wigren

Structural Genomics Consortium (SGC) and Center for Molecular Medicine, Department of Medicine, Karolinska Institutet , Stockholm

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CPCharlotta Preger
Charlotta Preger
EWEdvard Wigren
Edvard Wigren
EOElena Ossipova
Elena Ossipova
CMCarolyn Marks
Carolyn Marks
JLJohan Lengqvist
Johan Lengqvist
HPHelena Persson
Helena Persson
Aminoacyl-tRNA synthetases (aaRSs) have long been viewed as mere housekeeping proteins and have therefore often been overlooked in drug discovery. However, recent findings have revealed that many aaRSs have noncanonical functions, and several of the aaRSs have been linked to autoimmune diseases, cancer, and neurological disorders. Deciphering these roles has been challenging because of a lack of tools to enable their study. To help solve this problem, we have generated recombinant high-affinity antibodies for a collection of thirteen cytoplasmic and one mitochondrial aaRSs. Selected domains of these proteins were produced recombinantly in Escherichia coli and used as antigens in phage display selections using a synthetic human single-chain fragment variable library. All targets yielded large sets of antibody candidates that were validated through a panel of binding assays against the purified antigen. Furthermore, the top-performing binders were tested in immunoprecipitation followed by MS for their ability to capture the endogenous protein from mammalian cell lysates. For antibodies targeting individual members of the multi-tRNA synthetase complex, we were able to detect all members of the complex, co-immunoprecipitating with the target, in several cell types. The functionality of a subset of binders for each target was also confirmed using immunofluorescence. The sequences of these proteins have been deposited in publicly available databases and repositories. We anticipate that this open source resource, in the form of high-quality recombinant proteins and antibodies, will accelerate and empower future research of the role of aaRSs in health and disease.

1 November 2021 in Structure
Verified
Journal Article
Open access
ASAleksandra Szykowska
Aleksandra Szykowska
YCYu Chen
Yu Chen
TSThomas B. Smith
Thomas B. Smith
CPCharlotta Preger
Charlotta Preger
JYJingjing Yang
Jingjing Yang
ABAlex Bullock
Alex Bullock
Mutations in TREM2, a receptor expressed by microglia in the brain, are associated with an increased risk of neurodegeneration, including Alzheimer's disease. Numerous studies support a role for TREM2 in sensing damaging stimuli and triggering signaling cascades necessary for neuroprotection. Despite its significant role, ligands and regulators of TREM2 activation, and the mechanisms governing TREM2-dependent responses and its cleavage from the membrane, remain poorly characterized. Here, we present phage display generated antibody single-chain variable fragments (scFvs) to human TREM2 immunoglobulin-like domain. Co-crystal structures revealed the binding of two scFvs to an epitope on the TREM2 domain distal to the putative ligand-binding site. Enhanced functional activity was observed for oligomeric scFv species, which inhibited the production of soluble TREM2 in a HEK293 cell model. We hope that detailed characterization of their epitopes and properties will facilitate the use of these renewable binders as structural and functional biology tools for TREM2 research.

12 August 2023 in Rheumatology
Verified
Journal Article
Open access
PDF file
EGEveline Van Gompel
Eveline Van Gompel
DDDeniz Demirdal
Deniz Demirdal
CFCatia Fernandes-Cerqueira
Catia Fernandes-Cerqueira
BHBegum Horuluoglu
Begum Horuluoglu
AGAngeles Galindo-Feria
Angeles Galindo-Feria
ILIngrid E Lundberg
Ingrid E Lundberg
Clinical observations in patients with dermatomyositis (DM) and autoantibodies against the melanoma differentiation–associated protein 5 (MDA5) suggest that the autoantibodies contribute to the pathogenesis of MDA5(+) DM. To gain insight into the role of the anti-MDA5 autoantibodies, we aimed to identify their binding sites on the different domains of the MDA5 protein. We developed an in-house ELISA to assess the reactivity against the MDA5 domains (conformational epitopes) in plasma (n = 8) and serum (n = 24) samples from MDA5(+) patients with varying clinical manifestations and disease outcomes. The reactivities were also assessed using western blot (linearized epitopes). An ELISA-based depletion assay was developed to assess cross-reactivity among the different MDA5 domains. All eight plasma samples consistently showed reactivity towards conformational and linearized epitopes on the helicase domains of the MDA5 protein. The ELISA-based depletion assay suggests that anti-MDA5 autoantibodies specifically target each of the three helicase domains. Twenty-two of the 24 serum samples showed reactivity in the in-house ELISA and all 22 displayed reactivity towards the helicase domains of the MDA5 protein. Our data revealed that the main immunogenic targets of anti-MDA5 autoantibodies from MDA5(+) patients are the helicase domains. Considering that the helicase domains are responsible for the enzymatic activity and subsequent triggering of an inflammatory response, our findings suggest that binding of anti-MDA5 autoantibodies could alter the canonical activity of the MDA5 protein and potentially affect the downstream induction of a pro-inflammatory cascade.

29 May 2026 in Human Reproduction
Verified
Journal Article
Open access
MEMadison Edwards
Madison Edwards
AAAlexandra Amaral
Alexandra Amaral
ECEve M Carter
Eve M Carter
OAOliver Arnolds
Oliver Arnolds
KVKaren Vester
Karen Vester
CTClaudia Tredup
Claudia Tredup
STUDY QUESTION: Is the hydrolase ABHD2 required for progesterone-induced Ca2+ influx via CatSper and the resulting motility responses in human sperm? SUMMARY ANSWER: Progesterone-induced Ca2+ influx via CatSper and the resulting motility responses in human sperm do not require ABHD2 activity. WHAT IS KNOWN ALREADY: Sperm motility is tightly regulated by signalling pathways that are activated as sperm ascend the female reproductive tract, including progesterone triggering Ca2+ influx via the CatSper channel and inducing hyperactivated motility needed for fertilization. This process is thought to involve ABHD2, which may hydrolyze the endogenous CatSper inhibitor 2-arachidonoylglycerol (2-AG), thereby relieving inhibition and enabling calcium entry into the flagellum. STUDY DESIGN, SIZE, DURATION: Potent small molecule inhibitors of ABHD2 activity were synthesized, characterized, and used as tools to scrutinize the role of ABHD2 in activation of CatSper and regulation of sperm motility. PARTICIPANTS/MATERIALS, SETTING, METHODS: Derivatives of published ABHD2 inhibitors were optimized for in vitro potency and cellular activity and subsequently tested in human sperm motility and Ca2+ influx assays. MAIN RESULTS AND THE ROLE OF CHANCE: Progesterone does not activate ABHD2 in vitro. In addition, inhibition of ABHD2 in human sperm has no effect on progesterone-induced Ca2+ influx through CatSper nor on basal or progesterone-induced hyperactivated motility. This demonstrates that ABHD2 activity is, in fact, not required for the non-genomic action of progesterone on human sperm. LARGE SCALE DATA: None. LIMITATIONS, REASONS FOR CAUTION: We examined the effects of inhibition of the enzymatic activity of ABHD2. We cannot exclude that ABHD2 functions as a part of a larger multiprotein complex, in which it may play a structural role independent of its hydrolase activity. WIDER IMPLICATIONS OF THE FINDINGS: This study presents conclusive evidence that ABHD2 does not bind progesterone and that its hydrolase activity is not required for progesterone activation of CatSper and resulting changes in motility of human sperm. These results highlight the need for further research to elucidate the mechanism underlying the non-genomic action of progesterone on human sperm. STUDY FUNDING/COMPETING INTEREST(s): This publication is based on research funded by the Gates Foundation, reference IDs INV-040467 and ID INV-072213. The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions or policies of the Gates Foundation. LT, CB, and TS were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—project numbers 329621271 (CRU326; CB, TS), and 404595355 (Research Training Group ‘Chemical biology of ion channels (Chembion)’; LT, TS). This work was funded by the German Federal Ministry of Education and Research (BMBF) within the framework of Contraception Research, grant numbers 01GR2501A and 01GR2502A. A.A., K.V., A.T., N.D., A.H., M.W., and R.L. are employees of Nuvisan ICB GMBH, Berlin, Germany. Nuvisan is a recipient of a Gates Foundation grant. A.A. is associate editor of Human Reproduction Open.

2 December 2025 in bioRxiv
Verified
Preprint
Open access
EGEveline Van Gompel
Eveline Van Gompel
MGMarina Galesic
Marina Galesic
NDNicolas Delaroque
Nicolas Delaroque
KKKarolin Kern
Karolin Kern
RSRagnhild Stålesen
Ragnhild Stålesen
VJVijay Joshua
Vijay Joshua
Objectives: Autoantibodies targeting melanoma differentiation associated protein 5 (MDA5) are strongly associated with dermatomyositis (DM) and may contribute to its pathogenesis. Here we aimed to investigate MDA5 + B cells, their phenotype and generate MDA5 monoclonal antibodies to assess their epitope specificity. Methods: MDA5-reactive B cells were captured from peripheral blood of patients with anti-MDA5 + DM (n=3) using an MDA5-fluorescent probe. B cell receptor (BCR) sequences were analysed from single-sorted B cells (n=240). Selected clones were re-expressed as IgG1 monoclonal antibodies (mAbs, n=23). Reactivity was assessed using recombinant MDA5 protein constructs, peptide epitope mapping, ELISA, western blot and a commercial line blot assay. Results: Of 240 anti-MDA5 + sorted B cells, 23 BCRs were re-expressed as mAbs, two of which showed high reactivity and specificity for MDA5. These antibody sequences originated from one CD19 + IgD - CD27 - CD38 + and one CD19 + IgD - CD27 + CD38 + IgG + B cell with low somatic hypermutation (SHM). Both mAbs had nanomolar apparent affinity and bound to sites within the helicase domains of the MDA5 protein but with distinct epitope recognition. Serology screening confirmed targeting of a linear epitope identified in the mAb studies. Conclusion: Our results show that anti-MDA5 + B cells recognize the helicase domains, which are the enzymatically active domains of the protein. These results have implications for understanding the etiopathology of anti-MDA5 + DM and development of new antigen-specific therapies.

17 September 2025 in bioRxiv
Verified
Preprint
Open access
RARiham Ayoubi
Riham Ayoubi
EMEmma J. MacDougall
Emma J. MacDougall
IMIan McDowell
Ian McDowell
MBMichael S. Biddle
Michael S. Biddle
BFBárbara T. Ferreira
Bárbara T. Ferreira
CLCarl Laflamme
Carl Laflamme
Many proteins associated with amyotrophic lateral sclerosis (ALS) remain poorly characterized, in part because validated reagents for protein-level studies are scarce. We previously established knockout (KO)-based antibody characterization workflows and showed that widely used antibodies against the ALS-associated protein C9orf72 lacked specificity (Laflamme et al., 2019), and subsequently scaled this framework to systematically benchmark research antibodies, revealing that up to 61% do not perform as recommended by manufacturers (Ayoubi et al., 2023). Here, we extend this approach by establishing the ALS-Reproducible Antibody Platform (ALS-RAP) to evaluate antibodies against proteins encoded by ALS risk genes. We characterized 303 antibodies targeting 33 ALS-associated proteins using KO-based antibody characterization workflows to identify high-quality reagents for common experimental applications. Using validated antibodies, we profiled protein levels across human induced pluripotent stem cell (iPSC)-derived and primary neurological cell types, revealing diverse cellular distributions and higher protein levels for several ALS-associated proteins in glial and immune populations. Together, ALS-RAP provides a validated antibody toolbox and protein expression resource for studying ALS-associated proteins, supporting the view that ALS genetics converges on multicellular disease mechanisms involving both neuronal and glial populations.